Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients

被引:79
|
作者
Burkhardt, Christian [1 ]
Neuwirth, Christoph [1 ]
Sommacal, Andreas [2 ]
Andersen, Peter M. [3 ]
Weber, Markus [1 ]
机构
[1] Kantonsspital St Gallen, Neuromuscular Dis Unit, ALS Clin, St Gallen, Switzerland
[2] Kantonsspital St Gallen, Dept Pathol, St Gallen, Switzerland
[3] Umea Univ, Inst Pharmacol & Clin Neurosci, Umea, Sweden
来源
PLOS ONE | 2017年 / 12卷 / 05期
基金
瑞士国家科学基金会;
关键词
QUALITY STANDARDS SUBCOMMITTEE; NONINVASIVE VENTILATION; RESPIRATORY-FAILURE; PRACTICE PARAMETER; AMERICAN ACADEMY; FRENCH PATIENTS; DEATH; CARE; DIAGNOSIS; CRITERIA;
D O I
10.1371/journal.pone.0177555
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Non-invasive ventilation (NIV) and percutaneous gastrostomy (PEG) are guideline-recommended interventions for symptom management in amyotrophic lateral sclerosis (ALS). Their effect on survival is controversial and the impact on causes of death is unknown. Objective To investigate the effect of NIV and PEG on survival and causes of death in ALS patients. Methods Eighty deceased ALS patients underwent a complete post mortem analysis for causes of death between 2003 and 2015. Forty-two of these patients consented for genetic testing. Effects of NIV and PEG on survival and causes of death were analyzed in a multivariable Cox proportional hazard regression. Results Six patients, who requested assisted suicide causing drug-induced hypoxia, were excluded from final analysis. Respiratory failure was the main cause of death in 72 out of 74 patients. Fifteen out of 74 died of aspiration pneumonia 23/74 of bronchopneumonia and 8/74 of a combination of aspiration pneumonia and bronchopneumonia. Twenty died of hypoxia without concomitant infection, and six patients had pulmonary embolism alone or in combination with pneumonia. NIV (p = 0.01) and PEG (p<0.01) had a significant impact on survival. In patients using NIV bronchopneumonia was significantly more frequent (p <0.04) compared to non-NIV patients. This effect was even more pronounced in limb onset patients (p<0.002). Patients with C9orf72 hexanucleotide repeat expansions showed faster disease progression and shorter survival (p = 0.01). Conclusion The use of NIV and PEG prolongs survival in ALS. This study supports current AAN and EFNS guidelines which recommend NIV and PEG as a treatment option in ALS. The risk of bronchopneumonia as cause of death may be increased by NIV.
引用
收藏
页数:12
相关论文
共 39 条
  • [21] Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)
    Meyer, Thomas
    Funke, Andreas
    Muench, Christoph
    Kettemann, Dagmar
    Maier, Andre
    Walter, Bertram
    Thomas, Annett
    Spittel, Susanne
    BMC NEUROLOGY, 2019, 19 (01)
  • [22] Preservation of Vocal Function in Amyotrophic Lateral Sclerosis (ALS) Patients Following Percutaneous Dilatational Tracheostomy (PDT) and Adjuvant Therapies
    Yoo, Jae-Kook
    Kwon, Soon-Hee
    Yoon, Sul-Hee
    Lee, Jeong-Eun
    Jeon, Jong-Eun
    Chung, Je-Hyuk
    Lee, Sang-Yoon
    BIOMEDICINES, 2024, 12 (08)
  • [23] Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009-2011 and survival characteristics through 2015
    Punjani, Reshma
    Wagner, Laurie
    Horton, Kevin
    Kaye, Wendy
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2020, 21 (1-2) : 123 - 130
  • [24] Hospitalizations due to respiratory failure in patients with Amyotrophic Lateral Sclerosis and their impact on survival: a population-based cohort study
    Pisa, Federica Edith
    Logroscino, Giancarlo
    Battiston, Paolo Giacomelli
    Barbone, Fabio
    BMC PULMONARY MEDICINE, 2016, 16
  • [25] Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study
    Tortelli, R.
    Copetti, M.
    Panza, F.
    Fontana, A.
    Cortese, R.
    Capozzo, R.
    Introna, A.
    D'Errico, E.
    Zoccolella, S.
    Arcuti, S.
    Seripa, D.
    Simone, I. L.
    Logroscino, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 (06) : 1117 - 1125
  • [26] Role of the immune system in amyotrophic lateral sclerosis. Analysis of the natural killer cells and other circulating lymphocytes in a cohort of ALS patients
    Piccoli, Tommaso
    Castro, Francesca
    La Bella, Vincenzo
    Meraviglia, Serena
    Di Simone, Marta
    Salemi, Giuseppe
    Dieli, Francesco
    Spataro, Rossella
    BMC NEUROLOGY, 2023, 23 (01)
  • [27] Complexity of needs in amyotrophic lateral sclerosis (ALS) patients using the ENP-E scale in the north-eastern region of Spain
    Castro-Rodriguez, Emilia
    Azagra-Ledesma, Rafael
    Gomez-Batiste, Xavier
    Aguye-Batista, Amada
    Clemente-Azagra, Carlos
    Diaz-Herrera, Miguel Angel
    PALLIATIVE & SUPPORTIVE CARE, 2024, 22 (03) : 460 - 469
  • [28] A retrospective study of the clinical phenotype and predictors of survival in non-Caucasian Hispanic patients with amyotrophic lateral sclerosis
    Marisol Sanchez-Martinez, Claudia
    Alberto Choreno-Parra, Jose
    Nunez-Orozco, Lilia
    Placencia-Alvarez, Noel
    Marcela Alvis-Castano, Laura
    Guadarrama-Ortiz, Parmenides
    BMC NEUROLOGY, 2019, 19 (01)
  • [29] A preliminary comparison between ECAS and ALS-CBS in classifying cognitive-behavioural phenotypes in a cohort of non-demented amyotrophic lateral sclerosis patients
    Greco, Lucia Catherine
    Lizio, Andrea
    Casiraghi, Jacopo
    Sansone, Valeria Ada
    Tremolizzo, Lucio
    Riva, Nilo
    Solca, Federica
    Torre, Silvia
    Ticozzi, Nicola
    Filippi, Massimo
    Silani, Vincenzo
    Poletti, Barbara
    Lunetta, Christian
    JOURNAL OF NEUROLOGY, 2022, 269 (04) : 1899 - 1904
  • [30] Development of a clinical pathway for the attention of patients with amyotrophic lateral sclerosis in a regional network.: ALS Assistance Network-Comunidad de Madrid
    Rodriguez de Rivera, F. J.
    Grande, M.
    Garcia-Caballero, J.
    Munoz-Blanco, J.
    Mora, J.
    Esteban, J.
    Guerrero, A.
    Matias-Guiu, J.
    de Andres-Colsa, R.
    Buey, C.
    Diez-Tejedor, E.
    NEUROLOGIA, 2007, 22 (06): : 354 - 361